Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes

NACompletedINTERVENTIONAL
Enrollment

1,257

Participants

Timeline

Start Date

April 24, 2025

Primary Completion Date

May 4, 2025

Study Completion Date

May 4, 2025

Conditions
Tobacco Product Beliefs and Use
Interventions
BEHAVIORAL

Modified Risk Claim Type - None

Participants will view smokeless tobacco ads with no modified risk claim (control)

BEHAVIORAL

Product Brand - General Snus

Participants will views ads for the smokeless tobacco brand General Snus

BEHAVIORAL

Product Brand - Copenhagen

Participants will views ads for the smokeless tobacco brand Copenhagen

BEHAVIORAL

Modified Risk Claim Type - Multiple Diseases

Participants will view smokeless tobacco ads with a claim about lower risks for multiple diseases

BEHAVIORAL

Modified Risk Claim Type - Lung Cancer

Participants will either view smokeless tobacco ads with a modified risk claim about lower risks for lung cancer only

Trial Locations (1)

08901

Rutgers Institute for Nicotine & Tobacco Studies, New Brunswick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Rutgers, The State University of New Jersey

OTHER

NCT06927700 - Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes | Biotech Hunter | Biotech Hunter